Pathologic assessment of esophageal cancer following neoadjuvant therapy
- VernacularTitle:食管癌新辅助治疗后的病理评估
- Author:
Xijia FENG
1
;
Xiaoyan CHEN
1
;
Hecheng LI
1
Author Information
1. Department of Thoracic Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, P. R. China
- Publication Type:Journal Article
- Keywords:
Esophageal cancer;
neoadjuvant therapy;
efficacy evaluation;
tumor regression grading;
review
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2023;30(03):476-482
- CountryChina
- Language:Chinese
-
Abstract:
China is a country with a high incidence of esophageal cancer. Most patients are already in the locally advanced stage when first diagnosed. Preoperative neoadjuvant therapy followed by surgery has become the standard treatment mode for them. Closely related to prognosis, the evaluation of tumor response is essential. Response evaluation criteria in solid tumors is the gold standard to evaluate tumor response, but the lesions must meet the measurement standards. Tumor regression grading (TRG) systems are designed to classify regressive changes after neoadjuvant treatment based on histopathological results to reveal prognostic information. Concentrating on pathologic assessment of esophageal cancer following neoadjuvant therapy, this article reviews histopathological changes, commonly used TRG systems and current debate.
